Organon Canada extends the Remind Me Today! reminder program
TORONTO, Oct. 29 /CNW/ - Organon Canada continues to benefit from its
Remind Me Today! reminder program for its Linessa(R) and Nuvaring(R)
contraceptive brands. Women are delighted by the free telephone-based program
that helps them remember their contraceptives and Organon Canada is receiving
excellent feedback from their sales reps, physicians and patients.
Organon Canada initiated the Remind Me Today! telephone-based reminder
program in February 2007 in an effort to improve brand recognition and offer
women a valuable, cost-effective and lifestyle-friendly reminder solution. The
number of registrations continues to increase every month, exceeding
expectations with a retention rate of higher than 91%.
A closer look at the problem of medication non-compliance reveals that
unfilled and unused prescriptions are responsible for over 125,000 deaths in
the U.S. every year. (2004 Disease Management Directory and Guidebook; Pharma
MEMOTEXT(R) adherence programs are a very cost effective way to improve
compliance. Depending on the condition and the patient demographics,
telephone-based reminder programs have been shown to increase compliance
between 8% and 40%. The MEMOTEXT(R) personalized adherence solution sends
automated interactive daily text or voice call reminders to a patient's home,
office or cellular phone.
"Medication non-compliance is a serious issue for the healthcare
industry," explains Amos Adler, President of Enterprising Vision Inc.,
provider of MEMOTEXT(R). "Research shows that dropout rates for
anti-hypertensive and cholesterol-lowering drugs can be as high as 50%.
Billions of dollars are being lost across the board from government to
pharmaceutical companies - dollars that are directly attributable to
Organon Canada, makers of the Linessa(R) and NuvaRing(R) contraceptives,
understands the important relationship between successful healthcare outcomes
and the use of communications technology. "The Remind Me Today! program offers
women a highly effective lifestyle tool that takes the stress out of
remembering," says Meena Bhogal, Sr. Product Manager. "By offering our
patients this unique value-added service we are creating a very positive brand
experience that truly differentiates us in the marketplace."
Treating patients as partners in their own healthcare is key. "Patients
want to be educated and they want support with approaches that suit their
lifestyles. We know that interactive communications technology can bridge this
gap." says Adler.
Continuing its commitment to high quality products for women, Organon
Canada has renewed its contract with Toronto's MEMOTEXT(R) to provide women
with the custom designed Remind Me Today! program until 2009 with free
reminder messages until 2010.
Organon creates, manufactures and markets innovative prescription
medicines that improve the health and quality of human life. Through a
combination of innovation and business partnerships, Organon seeks to leverage
its position as a leading biopharmaceutical company in each of its core
therapeutic fields: fertility, gynecology and selected areas of anesthesia. It
has extensive expertise in neuroscience and a rich and focused R&D program.
Research areas also include immunology and specific areas of oncology. Organon
products are distributed in over 100 countries worldwide, of which more than
50 have an Organon subsidiary. Organon is the human healthcare business unit
of Akzo Nobel.
Safe Harbor Statement
This press release may contain forward-looking statements. These
forward-looking statements, addressing without limitation such key issues as
growth strategy, future financial results, market positions, and product
development, are based on current expectations of future events and
circumstances and can be identified by the fact that they use words such as
"will", "anticipate", "estimate", "expect", "project", "intend", "plan",
"believe", "target", "forecast", and other words and terms of similar meaning
in connection with any discussion of future operating or financial performance
or business prospects.
Such forward-looking statements should be carefully considered, and it
should be understood that many factors could cause forecasted and actual
results to differ from these forward-looking statements. Organon BioSciences
undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or circumstances, or
The forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Organon BioSciences'
business, particularly but without limitation including general industry
conditions and competition; economic conditions, such as interest rate and
currency exchange rate fluctuations; technological advances and patents
attained by competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and foreign health care
reforms and governmental laws and regulations; and trends toward health care
For further information:
For further information: Danielle Adler, Vice President, Business
Development, firstname.lastname@example.org, 1-877-636-6898, (647) 430-8233, Direct:
(416) 435-8131; Meena Bhogal, Sr. Product Manager, Contraception, Organon
Canada, email@example.com, (416) 290-2156